GREY:IMVIF - Post by User
Post by
Breakthoroughon May 22, 2021 3:56pm
510 Views
Post# 33254413
Comparison Stro-002 and DPX
Comparison Stro-002 and DPXDays ago Sutro Biopharma updated results of Stro-002 in ovarian (last were the 3rd of December). If you look at the DCR ("Disease Control rate", CR+PR+SD) during time, you see: Stro-002: 74% (23 patients) at 12 weeks ; 61% (19 pts) at16 weeks; 16% (5 pts) at 52 weeks. Maveropepimut: 79%; 37% at 26 weeks (6 months); 26'3% at 52 weeks (12 months). Looks like, with time, Maveropepimut (DPX) takes advantage. One can imagine that it will reflect in OS ("Overall Survival") too. Click here the link to www.sutrobio.com: https://finance.yahoo.com/news/sutro-biopharma-announces-additional-data-210000355.html